Reviewing Treatment Options for Advanced Renal Cell Carcinoma: Is There Still a Place for Tyrosine Kinase Inhibitor (TKI) Monotherapy?

Adv Ther · 2022 · PMC8756748 · PMID 35025061

Europe PMC DOI

hedged sentences

0.0780

closest p · 1.6× alpha

0.0780

boldest claim

The sentences

did not reach statistical significancep = 0.078so close (0.05 < p ≤ 0.1)

In the PFS analysis by IMDC risk category, PFS benefits with pembrolizumab + axitinib were generally consistent across the risk categories, although the results in the favourable-risk category did not reach statistical significance (HR 0.79; 95% CI 0.57–1.09; p = 0.078).

also in 111,027 other papers

borderline significantno p-value reported

In the prespecified subgroup analysis by IMDC risk category, patients in the favourable-risk category had a borderline significant PFS benefit with nivolumab + cabozantinib (HR 0.62; 95% CI 0.38–1.01), although the associated HR was higher than that of the intermediate-risk (HR 0.54; 95% CI 0.40–0.72) and poor-risk (HR 0.37; 95% CI 0.23–0.58) categories.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.